BFM
BCRX icon

Boothbay Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Boothbay Fund Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-73,700
Closed -$374K – 1527
2024
Q1 		$374K Buy
+73,700
New +$414K 0.01% 1124
2022
Q2 		– Sell
-67,300
Closed -$1.09M – 2252
2022
Q1 		$1.09M Buy
+67,300
New +$1.08M 0.03% 849

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Boothbay Fund Management's BCRX Position: Q4 2025 in Review

Boothbay Fund Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 50,000 shares — an estimated $380K sold.

Boothbay Fund Management first reported a position in BCRX in Q2 2018 and held it in 10 quarters. The position peaked at $13.2M in Q2 2024. 273 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Boothbay Fund Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 50,000 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $380K.
  • Boothbay Fund Management first reported a position in BioCryst Pharmaceuticals in Q2 2018 and held it in 10 quarters.
  • Boothbay Fund Management's BioCryst Pharmaceuticals position peaked at $13.2M in Q2 2024.
  • 273 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.